Strategic Growth StoryCatch Insights recently expanded through the acquisition of EmpiraMed, signaling a ramp in capabilities for virtual clinical studies and real world evidence. This presents a sales opportunity to cross-sell enhanced digital research platforms and services to existing EmpiraMed clients and partners who require scalable RWE solutions.

RWE Expertise With a focus on real world evidence and health outcomes measurement, the company positions itself as a leader in site-less registries and longitudinal data capture. Target health systems and biopharma sponsors seeking robust RWE analytics and patient-reported outcomes could benefit from StoryCatch’s InsightArc Suite.

Global Reach The acquisition broadens geographic and market reach in digital health technology for global studies. Opportunity exists to engage multinational sponsors and research consortia seeking scalable, privacy-conscious data collection and real-world data aggregation across diverse populations.

Smaller Firm Advantage Operating with a lean team yet connected to larger platforms hints at agile deployment and rapid integration capabilities. Prospects may value quick onboarding, personalized support, and flexible pricing for mid-market biopharma and contract research organizations.

Strategic Partnerships Past collaborations with organizations like LUNGevity demonstrate a track record in partnering for patient-centered outcomes research. Leverage this to propose joint programs, accelerators, and sponsored studies that leverage StoryCatch’s RWE tools to generate meaningful PRO and health outcome data.